Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 7 - Studien 61 bis 70 von insgesamt 76
- Rekrutierung läuft
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer [CR109264]
Molekulare Marker - Rekrutierung läuftPrävention von frühen Darmkrebserkrankungen - PEARL
- Rekrutierung läuftA Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma
- Rekrutierung läuft
PRODIGE 107- ENGIC 01- COLOSOTO
A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) in first-line treatment of patients non-eligible for a doublet/triplet chemotherapy with advanced unresectable KRAS G12C mutated colorectal adenocarcinoma
- Rekrutierung läuftPre-Operative Treatment in rEseCTable cOlon canceR(PROTECTOR/FIRE-10; AIO KRK0620; IAG-VO-0323)Prospective, randomized, open, multicenter Phase III trialto investigate the efficacy preoperative systemic therapy inadvanced colon cancer
- Rekrutierung läuftR-Pola-Glo – A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dosed R-CHOPMolekulare Marker
- Rekrutierung läuftA PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)
- Rekrutierung läuftRB-registry: a clinical registry for prospective data on retinoblastoma epidemiology and clinical course
- Rekrutierung läuftRandomized multi-centre open-label non-inferiority phase 3 clinical trial for patients with a stage IV childhood renal tumor comparing upfront Vincristine, Actinomycin-D and Doxorubicin (VAD, standard arm) with upfront Vincristine, Carboplatin and Etoposide (VCE, experimental arm)
- Rekrutierung läuftPatientenregister Seltene Histiocytosen